neutral
Recently
Biocon Q2 Profit Soars 428% on Biosimilar Growth
Biocon’s profit jumped 428% YoY to ₹85 crore, fueled by biosimilar expansion, margin control and global partnership strength.
Biocon reported a 428% year-on-year surge in second-quarter profit to ₹85 crore, driven by expanding biosimilar and generics operations. Revenue rose sharply amid strong US and Europe launches, improved production efficiency and better product mix. Management cited disciplined cost control and global partnership leverage for sustained margin gains. Analysts noted that Biocon’s renewed focus on innovation pipelines and geographic diversification could maintain double-digit growth, reinforcing investor confidence in the company’s competitiveness within India’s rapidly globalizing pharmaceutical sector.